Welcome, Guest. Please login or register.
March 29, 2024, 05:03:26 am

Login with username, password and session length


Members
  • Total Members: 37614
  • Latest: bondann
Stats
  • Total Posts: 772948
  • Total Topics: 66311
  • Online Today: 741
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 0
Guests: 445
Total: 445

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Maturation Inhibitor PA-457 will be used in combination with HAART this month  (Read 11071 times)

0 Members and 1 Guest are viewing this topic.

Offline blondbeauty

  • Member
  • Posts: 1,787
That is what I have just read in a spanish website. The original article is mexican:

http://www.vihpositivo.com/nuevamedicina100606.htm

Ilustration:

http://www.milenio.com/MediaCenter/Fotos/2006/Junio/10/ten-32-1pfg.jpg
The only member in these forums approved by WINBA: World International Nail and Beauty Association.
Epstein Barr +; CMV +; Toxoplasmosis +; HIV-1 +.
Counts when starting treatment:
V.L.:80.200 copies. CD4: 25%=503
Started Sustiva-Truvada 14/August/2006
Last V.L.count (Oct 2013): Undetectable
Last CD4 count (OCT 2013): 52%= 933

Offline Gilles

  • Member
  • Posts: 63
shame i cant read spanish.... :(

Offline chrisc

  • Member
  • Posts: 29
can anyone translay this info on p457

Offline blondbeauty

  • Member
  • Posts: 1,787
I prefer not to use one of those horrible automatic translations. So here goes a summary:
PA-457 from panacos is the first of a new family of tools against HIV infection. Reduces viral load in a 90% used as monotherapy. This same month trials will comence in combination with current antirretrovirals. If succesfull it will be in the market by 2009...
...PA-457 works in a completely different way: inactivating the formation of the caspid or the cone in the interior of the virus. A shell that protects the viral ARN from any external attack...looking through the microscope scientists could see how this works: HIv has a protein called Gag wich is cut into small pieces that form the caspid. PA-457 adheres to it preventing the protein gag from being cut properly and, instead of forming a protective cone, the caspid ends up being like a ball full of holes leaving the viral ARN unprotected. The virus is released from the host cell but its unable to infect other cells. Its a "dead" virus.
Another important fact is that PA-457 molecule only adheres to the gag protein after it has been formed preventing the formation of the caspid.
The trial will start with 48 patients with resistance issues combining their failing therapies with PA-457 or a placebo.
Panacos scientists are very excited but Allaway, reminds us there are still many steps to follow before it reaches the market and not before 2009.
This medication showed a 10% decrease in Viral load after a few hours of the first dose in humans.
It also showed a great antiviral activity in the animal model SCDI. It reduced viral load in mouses up to a 90%.
Pharmacinegetic tests in people were positive. Oral doses above 250 mg were well tolerated. In doses above 50 mg it mantained efective levels even after 24, which is something very desirable in these type of meds.

My transalation is not very good but the original is poorly writen and contents a bit untidy and messed up.
The study has been published in june´s Journal of Virology. A less tecnical version is available in "New Scientist"
The only member in these forums approved by WINBA: World International Nail and Beauty Association.
Epstein Barr +; CMV +; Toxoplasmosis +; HIV-1 +.
Counts when starting treatment:
V.L.:80.200 copies. CD4: 25%=503
Started Sustiva-Truvada 14/August/2006
Last V.L.count (Oct 2013): Undetectable
Last CD4 count (OCT 2013): 52%= 933

Offline cubbybear

  • Member
  • Posts: 510
Thanks heaps for the heads up and the translation Juan.

Cheers
Matt

Offline blondbeauty

  • Member
  • Posts: 1,787
The only member in these forums approved by WINBA: World International Nail and Beauty Association.
Epstein Barr +; CMV +; Toxoplasmosis +; HIV-1 +.
Counts when starting treatment:
V.L.:80.200 copies. CD4: 25%=503
Started Sustiva-Truvada 14/August/2006
Last V.L.count (Oct 2013): Undetectable
Last CD4 count (OCT 2013): 52%= 933

Offline blondbeauty

  • Member
  • Posts: 1,787
PA-457 will be named Bevirimat.
First hand information from Panacos. Phase 2b: http://phx.corporate-ir.net/phoenix.zhtml?c=75423&p=irol-newsArticle&ID=871292&highlight
The only member in these forums approved by WINBA: World International Nail and Beauty Association.
Epstein Barr +; CMV +; Toxoplasmosis +; HIV-1 +.
Counts when starting treatment:
V.L.:80.200 copies. CD4: 25%=503
Started Sustiva-Truvada 14/August/2006
Last V.L.count (Oct 2013): Undetectable
Last CD4 count (OCT 2013): 52%= 933

Offline J220

  • Member
  • Posts: 587
Tenfold reduction in a matter of hours...now that is what I called efficacy.
"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

Offline blondbeauty

  • Member
  • Posts: 1,787
Maybe these type of drugs (maturation inhibitors, integrase inhibitors...) are the piece of the puzzle we are missing in current HAART to clear the infection.
Remember this paragraf from a link I posted months ago?
"But Hamer also retains a guarded optimism shared by many reservoir researchers. "There's no evidence that HIV is genetically programmed to persist in the body," he says. Instead, he argues, the virus simply benefits from the limits of current therapy. "So eradication might actually turn out to be quite simple. Nobody knows. Adding one right drug to HAART may push the virus down to a level where it doesn't rebound. There's no evidence that's not the case."

http://www.iavireport.org/Issues/Issue9-5/reservoir.asp
The only member in these forums approved by WINBA: World International Nail and Beauty Association.
Epstein Barr +; CMV +; Toxoplasmosis +; HIV-1 +.
Counts when starting treatment:
V.L.:80.200 copies. CD4: 25%=503
Started Sustiva-Truvada 14/August/2006
Last V.L.count (Oct 2013): Undetectable
Last CD4 count (OCT 2013): 52%= 933

Offline J220

  • Member
  • Posts: 587
I was thinking about that statement precisely when I read the news about Bevirimat (might as well use their name now!). I think it's entirely possible that one day we'll hear that a volunteer (s) has been totally cleared as a result of participating in one of these trials that use new, effective therapies that block 100% of replication. Anti-tat for example (here I go again, talking about tat!), holds a lot of potential because it seems to totally block active replication. In any case, Bevirimat, whether it does clear infection or not, will be a fantastic thing because it seems to overcome resistance issues. J.
« Last Edit: June 17, 2006, 01:42:29 pm by J220 »
"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.